Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. It offers the following clinical stage product candidates: Mangoral, a liver imaging drug being developed for detection and localization of potential liver metastases; and Oncoral, a tablet-based formulation of the chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric cancer. The company was founded on May 17, 1999, and is headquartered in Malmö, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company